Nancy Olsen, MD
Rheumatology · Hershey, PANPI 1215996343
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,000 of the $3,618 with a category attached, or 82.9%. Gilead accounts for 82.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $3,000 and has fallen 97.1% since, to $87 in 2025.
Across 13 payments — averaging $278.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- UCB, Inc.$478
- Genentech USA, Inc.$125
- GE HealthCare$16
Across 41 payments — averaging $7097.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$108K
- Mallinckrodt Hospital Products Inc.$72K
- Amgen$54K
- Bristol Myers Squibb$23K
- Novartis$16K
- Pfizer$9K
- plus $9K from 2 others
What the payments were for
- Consulting fees$3,00083%
- Travel & lodging$37910%
- Food & beverage$2397%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $3,000 |
| UCB, Inc. | 4 | $478 |
| Genentech USA, Inc. | 7 | $125 |
| GE HealthCare | 1 | $16 |
How this compares
$3,618 in reported general payments places this provider in the 55th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 25 | $455,701 |
| Cosentyx Sensoready PenSecukinumab | 13 | $103,125 |
| Humira(Cf) PenAdalimumab | 13 | $89,417 |
| RinvoqUpadacitinib | 13 | $82,264 |
| Enbrel SureclickEtanercept | 11 | $78,524 |
| Hydroxychloroquine Sulfate | 185 | $8,115 |
| Prednisone | 312 | $1,512 |
| Azathioprine | 31 | $1,483 |
| Oxycodone Hcl | 58 | $1,466 |
| MethotrexateMethotrexate Sodium | 67 | $1,402 |
| Leflunomide | 48 | $1,400 |
| Celecoxib | 31 | $1,358 |
| Mycophenolate Mofetil | 11 | $1,160 |
| Colchicine | 13 | $804 |
| Sulfasalazine | 24 | $617 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Hershey
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
- Alan KivitzDuncansville$936K
- Paula HerringNewtown Square$920K
- Rohit AggarwalPittsburgh$810K
- Frederick MurphyDuncansville$494K
- Peter MerkelRadnor$479K
- Martin BergmanRidley Park$458K
- Alexis Ogdie-BeattyPhiladelphia$433K
- Ellen FieldBethlehem$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.